1Han SH, De Klerk JM, Zonnenberg BA et al. ^186Re-etidronate. Efficacy of palliative radionuclide therapy for painful bone meta-tases[J]. Q J Nucl Med, 2001 ;45(1 ) :84-90.
2Sciuto R, Tofani A, Festa A et al. Short and long-term effects of ^186 Re-l,l hydroxyethylidene diphosphonate in the treatment of painful bone metastases[ J]. J Nucl Med, 2000;41(4):647 -654.
3Sciuto R, Fesa A, Pasqualoni R et al. Metastatic bone pain palliation with 89-Sr and 186-Re-HEDP in breast cancer patients[J]. Breast Cancer Res,2001 ;66(2) :101- 109.
4Goddu SM, Bishayee A, Bouchet LG et al.Marrow toxicity of 33P-vesus 32Porthophosphate:implications for therapy of bone metastases[ J]. J Nucl Med,2000 ;41(5) :941 -951.
5Arteaga de Murphy C, Ferro Flores G, Pedraza Lopez M. Labelling of Re-ABP with 188Re for bone pain palliation [ J]. Appl Radiat Isot, 2001 ;54 ( 3 ) :435 - 442.
6Chakraborty S, Das T, Unni PR et al.177Lu labeled polyaminophosphonates as potential agents for bone pain palliation[ J ]. Nucl Med C ommun, 2002 ;23 ( 1 ) :67-74.
7Giammarile F, Mognetti T, Blondet C et al. Bone pain palliation with 85Sr therapy[J].J Nucl Med,1999;40(4) :585 -590.
8Bouchet LG, Bolch WE, Goddu SM et al.Considerations in the selection of radiopharmaceuticals for palliation of bone pain from metastatic osseous lesions[ J]. J Nucl Med,2000;41 (4) :682 -687.
9Kalkner KM, Westlin JE, Strang P.89Strontium in the management of painful sceleal metastases [ J ]. Anticancer Res,2000;20(2B) :1109 - 1114.
10Piffanelli A, Dafermou A, Giganti Met al.Radionuclide therapy for painful bone metastases. An Italian multicentre observational study. Writing Committee of an Ad Hoc Study Group[J]. Q J Nucl Med, 2001 ;45(1):100-107.
